2024
DOI: 10.1007/s11096-024-01802-1
|View full text |Cite
|
Sign up to set email alerts
|

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China

Wenwang Lang,
Qi Ai,
Yulong He
et al.
Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 39 publications
0
0
0
Order By: Relevance